Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients.

Abstract:

:Relaxin (RLX) is known to induce remodeling of benign stromal tissues through upregulation of matrix metalloproteases (MMPs). Recently, we could show that RLX also induces MMPs in breast cancer cells and enhances in vitro invasiveness. To investigate its potential role for progression of breast cancer in vivo, RLX serum concentrations were determined in 160 breast cancer patients during post-surgical follow-up. RLX concentrations in cancer patients were significantly higher than in a control population of healthy blood donors and patients with various other diseases (0.47 versus 0.29 ng/ml, p < 0.0001). There was a significant difference between patients with metastases (0.62 ng/ml) and those without (0.38 ng/ml, p < 0.0001). Overall survival was shorter in RLX-positive ( > 0.4 ng/ml) than in RLX-negative patients (p = 0.016). Cox regression analysis showed that RLX was not an independent variable, in contrast to metastatic disease and primary lymph node involvement. Taken together, the detection of elevated RLX concentrations especially in patients with metastases supports the assumption that there is a role for RLX in tissue remodeling during breast cancer progression.

authors

Binder C,Simon A,Binder L,Hagemann T,Schulz M,Emons G,Trümper L,Einspanier A

doi

10.1023/B:BREA.0000041622.30169.16

subject

Has Abstract

pub_date

2004-09-01 00:00:00

pages

157-66

issue

2

eissn

0167-6806

issn

1573-7217

pii

5276002

journal_volume

87

pub_type

杂志文章
  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract::Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title:Breast cancer research and treatment

    pub_type: 已发布勘误

    doi:10.1007/s10549-016-3752-9

    authors: Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期:2016-04-01 00:00:00

  • Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.

    abstract::We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-005-5199-2

    authors: Kokko R,Hakama M,Holli K

    更新日期:2005-10-01 00:00:00

  • The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

    abstract::A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependent mitogens, antibody production, lymphocy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665692

    authors: Gallo F,Morale MC,Sambataro D,Farinella Z,Scapagnini U,Marchetti B

    更新日期:1993-09-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract::In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806751

    authors: Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期:1981-01-01 00:00:00

  • What is the future of magnetic nanoparticles in the axillary management of breast cancer?

    abstract::Magnetic nanoparticles (MNPs) possess unique properties, which make them highly attractive for medical applications. The use of MNPs in surgery has mainly been focused on their role in the identification of metastatic lymph node involvement. There have been developments within this field, including ongoing and newly c...

    journal_title:Breast cancer research and treatment

    pub_type: 社论

    doi:10.1007/s10549-013-2801-x

    authors: Ahmed M,Douek M

    更新日期:2014-01-01 00:00:00

  • Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.

    abstract::Elevated levels of circulating estrogens and androgens are linked to higher breast cancer risk among postmenopausal women; however, little is known about hormone levels within the breast. Hormone concentrations within the breast may not be reflected in the blood and are likely important contributors to breast carcinog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1734-5

    authors: Falk RT,Gentzschein E,Stanczyk FZ,Garcia-Closas M,Figueroa JD,Ioffe OB,Lissowska J,Brinton LA,Sherman ME

    更新日期:2012-01-01 00:00:00

  • Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.

    abstract::Although preoperative magnetic resonance imaging (MRI) can detect mammographically occult contralateral breast cancers (CBCs) among women with ductal carcinoma in situ (DCIS), the impact of MRI on the incidence of subsequent CBC events is unclear. We examined whether MRI use decreases CBC occurrences and detection of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3858-0

    authors: Wang SY,Long JB,Killelea BK,Evans SB,Roberts KB,Silber A,Gross CP

    更新日期:2016-07-01 00:00:00

  • Breast cancer risk factors and second primary malignancies among women with breast cancer.

    abstract:PURPOSE:To examine the association between breast cancer risk factors and second primary cancers (independent diagnoses occurring at least 12 months after the initial breast cancer diagnosis) among breast cancer survivors. METHODS:In this population-based study, cancer outcomes among breast cancer survivors first diag...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9446-y

    authors: Trentham-Dietz A,Newcomb PA,Nichols HB,Hampton JM

    更新日期:2007-10-01 00:00:00

  • Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.

    abstract:PURPOSE:A positive margin after breast conserving surgery has consistently been shown to be a significant predictor for ipsilateral breast tumor recurrence. Currently, there is no standard for intraoperative margin assessment during lumpectomy, and up to 20% of cases result in positive margins. MarginProbe is a device ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05773-5

    authors: LeeVan E,Ho BT,Seto S,Shen J

    更新日期:2020-08-01 00:00:00

  • The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells.

    abstract::Cell migration is essential in many diverse processes ranging from embryonic development to wound healing and immune response. Cancer cells have recently been shown to utilize chemoattraction mechanisms mediated by chemokines and their respective receptors, e.g., the CXCL12/CXCR4 pathway normally found in leukocytes. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9504-0

    authors: Schmid BC,Rezniczek GA,Fabjani G,Yoneda T,Leodolter S,Zeillinger R

    更新日期:2007-12-01 00:00:00

  • Medical costs associated with metastatic breast cancer in younger, midlife, and older women.

    abstract:PURPOSE:We estimated average medical costs due to metastatic breast cancer (mBC) among younger (aged 18-44), midlife (aged 45-64), and older women (aged 65 and older) by phase of care: initial, continuing, and terminal. METHODS:We used 2003-2014 North Carolina cancer registry data linked with administrative claims fro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05654-x

    authors: Trogdon JG,Baggett CD,Gogate A,Reeder-Hayes KE,Rotter J,Zhou X,Ekwueme DU,Fairley TL,Wheeler SB

    更新日期:2020-06-01 00:00:00

  • Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.

    abstract:PURPOSE:Previous work found that lower BMI is associated with a pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer. Relative dose intensity (RDI) of chemotherapy is an important marker of treatment tolerability. We hypothesized that patients with low BMI would have higher RDI than p...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05994-8

    authors: Usiskin I,Li F,Irwin ML,Cartmel B,Sanft T

    更新日期:2020-10-30 00:00:00

  • Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone

    abstract:BACKGROUND:This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective. METHODS:A probabilistic Markov model was developed using the 5-year com...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9483-6

    authors: Locker GY,Mansel R,Cella D,Dobrez D,Sorensen S,Gandhi SK,ATAC Trialists' Group.

    更新日期:2007-12-01 00:00:00

  • Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.

    abstract::Circulating tumor cells are commonly observed in the peripheral blood of advanced breast cancer patients. We tested the feasibility of tumor cell detection in the cerebrospinal fluid (CSF) and studied its clinical relevance in leptomeningeal metastasis (LM) of breast cancer. CSF samples were collected from 38 metastat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3610-1

    authors: Lee JS,Melisko ME,Magbanua MJ,Kablanian AT,Scott JH,Rugo HS,Park JW

    更新日期:2015-11-01 00:00:00

  • Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS).

    abstract::Management of localized breast cancer now commonly involves a breast-sparing approach combined with systemic adjuvant therapy resulting in improved cosmetic results and patient survival. Reducing dietary fat intake represents a conceptually new approach to further improve outcome of patients with resected breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01834637

    authors: Chlebowski RT,Rose D,Buzzard IM,Blackburn GL,Insull W Jr,Grosvenor M,Elashoff R,Wynder EL

    更新日期:1992-01-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract::A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1023081624133

    authors: Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期:2003-04-01 00:00:00

  • MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC).

    abstract::HER2/neu overexpression leads to poorer prognosis and higher risk of disease reoccurrence in breast cancer patients. The causative factors responsible for increasing HER2/neu expression levels on mammary cells are not known. We investigated whether factors associated with inflammation or metastasis could induce HER2/n...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2191-5

    authors: Fatunmbi M,Shelton J,Aronica SM

    更新日期:2012-09-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract::Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006190820231

    authors: Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期:1999-02-01 00:00:00

  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

    abstract:PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06012-7

    authors: Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

    更新日期:2020-11-18 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract::The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9312-y

    authors: Paliouras M,Diamandis EP

    更新日期:2007-03-01 00:00:00

  • A plea for the biopsy marker: how, why and why not clipping after breast biopsy?

    abstract::In the last decade, percutaneous breast biopsies have become a standard for the management of breast diseases. Biopsy clips allow for precise lesion localization, thus minimizing the volume of breast to be resected at the time of surgery. With the development of many imaging techniques (including mammography, sonograp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-011-1847-x

    authors: Thomassin-Naggara I,Lalonde L,David J,Darai E,Uzan S,Trop I

    更新日期:2012-04-01 00:00:00

  • Current status of paclitaxel in the treatment of breast cancer.

    abstract::Paclitaxel is a highly active single agent as therapy for previously untreated as well as doxorubicin-refractory metastatic breast cancer, with associated response rates of 62% and 20-48%, respectively. Complete responses with paclitaxel occur chiefly in breast cancer patients whose metastatic disease has not been pre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666068

    authors: O'Shaughnessy JA,Cowan KH

    更新日期:1995-01-01 00:00:00

  • Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.

    abstract::Goserelin ('Zoladex'), a luteinizing hormone-releasing hormone (LHRH) agonist induces reversible ovarian ablation in premenopausal women. It is the most extensively studied LHRH agonist for the treatment of breast cancer and data from a large clinical trial program show that, alone or in combination with tamoxifen, go...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1020309715942

    authors: Jonat W

    更新日期:2002-10-01 00:00:00

  • Breast cancer in women under 30 years of age.

    abstract::Conflicting opinions exist concerning clinical and pathological presentation, as well as evolution and prognosis, of breast cancer in young women. The roles of associated pregnancy and lactation on these parameters is also unclear. These two conditions are studied in the present work through the comparison of two brea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF02235745

    authors: Tabbane F,el May A,Hachiche M,Bahi J,Jaziri M,Cammoun M,Mourali N

    更新日期:1985-01-01 00:00:00

  • High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.

    abstract:BACKGROUND:High insulin levels have been associated with poor outcomes in breast cancer. Our goal was to investigate whether hyperinsulinemia was associated with insulin resistance in a cohort of newly diagnosed locoregional breast cancer patients and to examine associations of hyperinsulinemia with the broader insulin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0019-0

    authors: Goodwin PJ,Ennis M,Bahl M,Fantus IG,Pritchard KI,Trudeau ME,Koo J,Hood N

    更新日期:2009-04-01 00:00:00

  • Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.

    abstract:PURPOSE:CIPN is a common, debilitating, and dose-limiting side effect of chemotherapy. Here, we describe characteristics of patients with CIPN using both patient-reported outcomes (PRO) and quantitative sensory testing (QST). METHODS:Breast cancer survivors with persistent moderate to severe CIPN defined by a rating o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05416-4

    authors: Zhi WI,Chen P,Kwon A,Chen C,Harte SE,Piulson L,Li S,Patil S,Mao JJ,Bao T

    更新日期:2019-12-01 00:00:00

  • Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations.

    abstract:BACKGROUND:In 2003, for the first time, US breast cancer incidence rates have fallen. Experts argue whether this is due to the reduced uptake of screening mammography or to lower use of Hormone Replacement Therapy (HRT). This study aims to disentangle the respective impact of screening and HRT on age-incidence rates an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9554-3

    authors: Verkooijen HM,Koot VC,Fioretta G,van der Heiden M,Schipper ME,Rapiti E,Peeters PH,Peterse JL,Bouchardy C

    更新日期:2008-02-01 00:00:00

  • Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

    abstract::Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-010-1257-5

    authors: Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

    更新日期:2011-02-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract::The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803781

    authors: Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期:1996-01-01 00:00:00

  • Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.

    abstract::In previous studies, we observed that regulation of expression of CD200, both on cells of a transplantable breast cancer, EMT6, and of the host, as well as of the receptor, CD200R in host mice, regulated local tumor growth and metastasis in immunocompetent animals. This in turn led to an improved ability to document i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2735-3

    authors: Gorczynski RM,Chen Z,Khatri I,Podnos A,Yu K

    更新日期:2013-11-01 00:00:00